Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: SPOR Networks in Chronic Disease - LOI

University of British Columbia

$50,000.00

Canadian Pipeline for Alzheimer's Disease Therapeutics (cPAD)

EF 2014-15

Résumé
Alzheimer's disease (AD) and related causes of dementia is becoming more common among older individuals in Canada and across the world. While progress is being made, no effective drugs for AD and other dementias is available for patients. In this grant proposal, we address the critical need for new drugs in AD and the dementias by pooling together scientists and resources across the country to accelerate drug development. We take advantage of existing infrastructure to perform dementia research, funded by taxpayer money, to implement our innovative program. The program is further integrated with patient representatives and health policy makers to ensure patient concerns and priorities guides the drug development plan, and that results can quickly lead to health policy changes. Our proposed drug development network aims to produce 2 drugs with promising treatment potential AD or the dementias within a 5-year period. the results could have a tangible effect on the treatment of dementia, and the preservation of healthy aging across the nation.
Programme
SPOR Networks in Chronic Disease - LOI
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
323919
Name
Feldman Howard
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
SPOR Networks in Chronic Disease
Projecttitle
Canadian Pipeline for Alzheimer's Disease Therapeutics (cPAD)
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
SPOR Networks in Chronic Disease - LOI
Keyworddelim
Alzheimer Disease; Dementia; Drug Development; Network; Preclinical
Abstract
Alzheimer's disease (AD) and related causes of dementia is becoming more common among older individuals in Canada and across the world. While progress is being made, no effective drugs for AD and other dementias is available for patients. In this grant proposal, we address the critical need for new drugs in AD and the dementias by pooling together scientists and resources across the country to accelerate drug development. We take advantage of existing infrastructure to perform dementia research, funded by taxpayer money, to implement our innovative program. The program is further integrated with patient representatives and health policy makers to ensure patient concerns and priorities guides the drug development plan, and that results can quickly lead to health policy changes. Our proposed drug development network aims to produce 2 drugs with promising treatment potential AD or the dementias within a 5-year period. the results could have a tangible effect on the treatment of dementia, and the preservation of healthy aging across the nation.
Competitiondate
201501
Approvedterm2
1 yr 0 mth
Pinamesdelim
Feldman, Howard; Davidson, Heather; Greenberg, Barry D; Nygaard, Haakon B; Rockwood, Kenneth
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~